Staff members inspect equipment at a production workshop of Novo Nordisk (China) Pharmaceuticals on Feb 25. The parent company will invest US$30.5 million to set up a new unit at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone. - Xinhua
BEIJING (China Daily/ANN): Tailwinds are not only offsetting the negative economic impact of Covid-19 on China's healthcare industry but also speeding up its evolution, heralding restructuring, expansion and rise in foreign investment flows, industry insiders said.
The glad tidings promise to make health one of society's top priorities as the nation swears by the new dual-circulation pattern for high-quality development in the post-pandemic era.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
